Hector F. DeLuca

Hector Floyd DeLuca (born in Pueblo, Colorado in 1930) is a University of Wisconsin–Madison (UW-Madison) emeritus professor and former chairman of the university's biochemistry department. DeLuca is well known for his research involving Vitamin D, from which several pharmaceutical drugs are derived, including those to treat conditions such as kidney failure, osteoporosis, and psoriasis.

DeLuca trained almost 160 graduate students Licensing of his technology, through the Wisconsin Alumni Research Foundation (WARF), has generated tens of millions of dollars in revenue for the university.

In addition, DeLuca founded three biotechnology companies: Deltanoid Pharmaceuticals, Bone Care International Inc, and Tetrionics. He was awarded the Bolton S. Corson Medal of the Franklin Institute in 1985. Three buildings on the Wisconsin campus, including the DeLuca Biochemistry Building, were named in his honor in 2014.

Early life and education

Early life Hector F. DeLuca was born in Pueblo, Colorado, in 1930, and grew up on a vegetable farm outside the city. This rural upbringing, combined with the industrial backdrop of Pueblo at the foot of the Rocky Mountains, shaped his early interest in science and exploration. His doctoral dissertation is entitled “The Effect of Vitamin D on Alkaline Phosphatase in the Rachitic Rat”. Upon Steenbock's retirement in 1955, DeLuca took over the lab, continuing his mentor’s pioneering work. 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3): DeLuca further identified this metabolite as the active hormonal form of Vitamin D, produced in the kidneys. This compound regulates calcium and phosphate metabolism, ensuring proper bone formation and maintenance. Osteoporosis: Enhancing bone density and reducing fracture risk, particularly in postmenopausal women and aging populations

In 2001, DeLuca founded Deltanoid Pharmaceuticals, a biotechnology company dedicated to advancing therapies derived from Vitamin D research. Deltanoid focused on translating laboratory findings into clinical applications, particularly for rare and complex diseases. This venture highlights DeLuca’s commitment to bridging the gap between academic discovery and real-world medical solutions.

DeLuca founded Tetrionics in 1989, later bought by Sigma-Aldrich in 2004. Tetrionics manufactured pharmaceutical ingredients, including Paricalcitol (trade name Zemplar(™)), which is used to treat secondary hyperparathyroidism.

Academic and professional roles DeLuca served as the chairman of the Biochemistry Department at UW-Madison for 30 years. Under his leadership, the department became a global center for vitamin and hormone research. He fostered a culture of excellence, attracting top-tier faculty and students while ensuring the department remained at the forefront of scientific innovation. with a court case brought by RIMAC against WARF, alleging that RIMAC scientists had been the first to successfully synthesize 1-alpha-HCC and DeLuca’s lab had information gained from a paper sent to them for peer review by RIMAC. The case was settled out of court in 1987 with WARF paying an unknown sum, and RIMAC relinquishing patent rights. CALS Distinguished Service Award (UW - Madison, 2007) – Celebrating his legacy as an alumnus and a pioneer in biochemistry Hilldale Award in the Physical Sciences (UW - Madison, 1993) – Celebrating his exceptional teaching and research achievements Bolton S. Corson Medal (Franklin Institute, 1985) – For his exceptional contributions to biochemistry and Vitamin D research National Academy of Sciences (1979) – Elected as a member in recognition of his distinguished and continuing achievements in original research American Academy of Arts and Sciences (1978) – elected as a member in recognition of excellence in the sciences, and commitment to the ideals of the Academy